Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty
- 27 August 2008
- journal article
- research article
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 27 (2) , 183-188
Abstract
Earlier osteodensitometric results of femoral periprosthetic bone showed that postoperative antiresorptive treatment with alendronate following total hip arthroplasty (THA) reduces the periprosthetic bone loss that commonly occurs in the first months after surgery. However, whether alendronate can prevent periprosthetic bone loss over the long term, or if bone loss occurs after discontinuing alendronate is unknown. Femoral periprosthetic bone mineral density (BMD) was assessed in 49 patients 6 years after cementless total hip arthroplasty using dual energy X‐ray absorptiometry. Twenty‐nine patients were treated postoperatively with alendronate and 20 control patients received no treatment. All patients were followed up at 12 months after surgery in a prospective randomized study. The bone mineral density was evaluated in 7 regions of interest according to the Gruen protocol. Six years after total hip arthroplasty, no significant changes were detected in femoral periprosthetic BMD when compared with results at 1 year, and the bone loss in patients with postoperative alendronate treatment was still significantly less than those without treatment. These results suggest that the prevention of femoral periprosthetic bone loss following THA achieved by postoperative antiresorptive treatment with alendronate is of long‐standing effect, and further bone loss does not occur after the first postoperative year. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:183–188, 2009Keywords
This publication has 21 references indexed in Scilit:
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal modelJournal of Orthopaedic Science, 2007
- Clinical and radiological outcome of total hip replacement five years after pamidronate therapyThe Journal of Bone and Joint Surgery. British volume, 2006
- Dosisabhängige Prophylaxe des frühen periprothetischen Knochenschwundes durch AlendronatZeitschrift für Orthopädie und ihre Grenzgebiete, 2002
- Alendronate Reduces Periprosthetic Bone Loss After Uncemented Primary Total Hip Arthroplasty: A Prospective Randomized StudyJournal of Bone and Mineral Research, 2001
- Monitoring of Periprosthetic BMD After Uncemented Total Hip Arthroplasty with Dual-Energy X-Ray Absorptiometry—a 3-Year Follow-Up StudyJournal of Bone and Mineral Research, 2001
- Effect of Pamidronate in Preventing Local Bone Loss After Total Hip Arthroplasty: A Randomized, Double-Blind, Controlled TrialJournal of Bone and Mineral Research, 2001
- Migration, Particles, and Fluid PressureClinical Orthopaedics and Related Research, 1998
- Patient-related risk factors for early revision of total hip replacements: A population register-based case-control study of 674 revised hipsActa Orthopaedica, 1997
- Bone mineral density around femoral stems DXA measurements in 22 porous-coated implants after 5 yearsActa Orthopaedica, 1995